The criminalization of drugs is a modern phenomenon, emerging only in the 20th century. For most of history, substances were legal and readily available for spiritual, religious, and recreational use, reframing the current prohibited status as a historical aberration, not the norm.

The opioid epidemic is fueled by a lack of things to do, as community hubs like theaters, parks, and libraries have disappeared. Rebuilding this 'social infrastructure' provides purpose and connection, acting as a powerful, non-clinical intervention against drug addiction.

Unlike Canada's top-down legalization, the US's state-by-state approach has built significant, isolated infrastructure. Federal approval would unleash this capacity for interstate commerce, allowing production to consolidate in ideal locations and dramatically reshaping the national supply chain.

Regulatory uncertainty has depressed valuations for brands that burned capital fighting state-level rules. This creates an arbitrage window for investors to acquire established brands at a discount before federal rescheduling unlocks their true market potential and valuations rebound.

The current challenging market forces cannabis startups to be incredibly resourceful, mirroring the industry's long history of operating in grey or illicit markets. This "survival of the fittest" environment ultimately strengthens the best companies.

Because cannabis is a Schedule I drug, tax code 280E prevents businesses from deducting standard operating expenses, resulting in crippling effective tax rates. Federal rescheduling would eliminate this, instantly making many struggling companies profitable overnight.

The true 'gateway' effect of cannabis isn't leading to harder substance use, but rather introducing marginalized populations into the criminal justice system. Despite similar usage rates across races, selective enforcement disproportionately funnels Black and brown people into a cycle of arrests and incarceration.

The bill federally legalized hemp, creating a loophole for brands to legally ship THC products direct-to-consumer and run normal CPG ads. This gave hemp-based companies a massive efficiency advantage over state-regulated operators burdened by taxes and marketing restrictions.

The drug crisis may be perpetuated by a system that benefits from its existence, including pharmaceutical companies, bureaucracies, and consultants. The proposed solution of providing more prescribed drugs is framed as ironically profiting the same industry that helped cause the opioid crisis, creating a perverse incentive against recovery.